title: New treatment strategies for patients with triple-negative breast cancer.
abstract: OBJECTIVE
  Although patients with hormone receptor-positive and/or HER2-positive breast cancer benefit from endocrine and HER2-targeted agents in addition to combination chemotherapy regimens, patients with triple-negative breast cancer (TNBC) suffer from a particularly unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. Novel treatment options are urgently needed to improve prognosis of these patients as well.
  
  
  RESULTS
  Potential options for optimized therapy of patients with TNBC consist in, first, optimization of chemotherapy through optimization of chemotherapy regimens with may be reached through optimized (i.e., dose-dense) scheduling, second, optimization of chemotherapy through introduction of novel chemotherapy agents (such as platinum compounds as alternative of additional chemotherapy), third, identification and development of novel targeted agents, and fourth, identification of patients with or without response through biomarkers to individual treatments to allow for a more personalized treatment approach.
  
  
  CONCLUSIONS
  We summarize recent findings for novel treatment options particularly focusing on platinum-based chemotherapy, potential novel targeted therapies such as antiangiogenic agents or inhibition of poly-A-ribose-polymerase, and prognostic/predictive biomarkers such as tumor-infiltrating lymphocytes or BRCA.
authors.affiliation: Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Schleswig-Holstein , Lübeck, Germany.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Liedtke
authors.forename: Achim
authors.initials: A
authors.lastname: Rody
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000097:blood; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D057285:Precision Medicine; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects*; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases